<!--

COPYRIGHT NOTICE

This file is part of the "Universal Biomedical Skills" project.

Copyright (c) 2026 MD BABU MIA, PhD <md.babu.mia@mssm.edu>

All Rights Reserved.

#

This code is proprietary and confidential.

Unauthorized copying of this file, via any medium is strictly prohibited.

#

Provenance: Authenticated by MD BABU MIA

-->

Cytokine Storm Analysis Agent

The Cytokine Storm Analysis Agent provides comprehensive AI-driven analysis of cytokine release syndrome (CRS) and hyperinflammatory states. It integrates cytokine profiling, clinical parameters, and immunological markers for early prediction, severity grading, and treatment guidance in CAR-T therapy, sepsis, and viral infections.

When to Use This Skill

• When monitoring CAR-T patients for cytokine release syndrome risk.
• To predict CRS severity and timing post-immunotherapy.
• For analyzing cytokine panels in sepsis and viral infections (COVID-19).
• When guiding tocilizumab/siltuximab anti-IL-6 therapy decisions.
• To distinguish CRS from ICANS, HLH, and other inflammatory syndromes.

Core Capabilities

1. CRS Risk Prediction: ML models predict CRS development and severity from baseline factors (tumor burden, disease type, CAR-T product).

1. Real-Time Monitoring: Track cytokine dynamics (IL-6, IFN-γ, IL-10, ferritin) with early warning alerts.

1. Severity Grading: Automated ASTCT CRS grading using clinical parameters and biomarkers.

1. Differential Diagnosis: Distinguish CRS from HLH/MAS, ICANS, infection, and tumor lysis syndrome.

1. Treatment Guidance: AI-driven recommendations for tocilizumab, corticosteroids, and supportive care.

1. Outcome Prediction: Model response to anti-cytokine therapy and overall outcomes.

Cytokine Panel Analysis

| Cytokine | Role in CRS | Kinetics | Therapeutic Target | |----------|-------------|----------|-------------------| | IL-6 | Central mediator | Early peak | Tocilizumab, Siltuximab | | IFN-γ | T-cell activation | Early | Emapalumab | | IL-1β | Inflammasome | Early | Anakinra | | IL-10 | Regulatory | Variable | - | | TNF-α | Pro-inflammatory | Early | Infliximab (caution) | | IL-2 | T-cell expansion | Early | - | | GM-CSF | Myeloid activation | Sustained | Lenzilumab |

ASTCT CRS Grading (Automated)

| Grade | Fever | Hypotension | Hypoxia | |-------|-------|-------------|---------| | 1 | ≥38°C | None | None | | 2 | ≥38°C | Responsive to fluids | Low-flow O2 | | 3 | ≥38°C | One vasopressor | High-flow O2 | | 4 | ≥38°C | Multiple vasopressors | Ventilation |

Workflow

1. Input: Cytokine levels, vital signs, laboratory values, treatment history.

1. Risk Assessment: Baseline CRS risk stratification pre-therapy.

1. Monitoring: Real-time cytokine tracking with trend analysis.

1. Grading: Automated CRS grade assignment per ASTCT criteria.

1. Differential: Rule out mimics (infection, HLH, ICANS).

1. Treatment: Generate management recommendations.

1. Output: CRS risk score, grade, differential diagnosis, treatment plan.

Example Usage

User: "Monitor this CAR-T patient's cytokine levels and predict CRS severity."

Agent Action:

bash
python3 Skills/Immunology_Vaccines/Cytokine_Storm_Analysis_Agent/crs_analyzer.py \
    --patient_data demographics.json \
    --cytokines cytokine_panel.csv \
    --vitals vital_signs.csv \
    --labs laboratory_values.csv \
    --cart_product tisagenlecleucel \
    --day_post_infusion 5 \
    --model crs_predictor_v3 \
    --output crs_report.json

AI/ML Models

CRS Risk Prediction:

• Features: tumor burden (LDH), lymphodepletion intensity, CAR-T dose, disease type
• Model: Gradient boosting with SHAP interpretability
• Performance: AUC 0.82-0.88 for severe CRS

Severity Trajectory:

• Time-series modeling of cytokine dynamics
• LSTM networks for temporal patterns
• Early warning 24-48 hours before clinical deterioration

Treatment Response:

• Tocilizumab response prediction
• Corticosteroid escalation timing
• ICU admission risk

Differential Diagnosis Decision Tree

Fever + Elevated Cytokines
          |
    CAR-T context?
    /           \
  Yes            No
   |              |
Hypotension?   Infection workup
   |              |
  CRS          Sepsis vs viral
   |
Neuro symptoms?
   |
  ICANS vs CRS
   |
Ferritin >10,000?
   |
  HLH/MAS evaluation

Clinical Decision Support

Tocilizumab Indication:

• Grade 2+ CRS
• Rapidly rising cytokines
• High-risk baseline features

Corticosteroid Indication:

• Tocilizumab-refractory CRS
• ICANS any grade
• Grade 3+ CRS

Prerequisites

• Python 3.10+
• scikit-learn, XGBoost for ML
• Time-series analysis libraries
• FHIR client for EHR integration

Related Skills

• CART_Design_Optimizer_Agent - For CAR-T design
• TCell_Exhaustion_Analysis_Agent - For T-cell function
• Clinical_NLP - For extracting symptoms from notes

Special Populations

1. Pediatric: Different baseline cytokine ranges
2. Post-COVID: Altered inflammatory responses
3. Bridging Therapy: Impact on CRS risk
4. Concurrent Infection: Confounding cytokine elevation

Author

AI Group - Biomedical AI Platform

<!-- AUTHOR_SIGNATURE: 9a7f3c2e-MD-BABU-MIA-2026-MSSM-SECURE -->